Dr. Tiacci on Vemurafenib and Rituximab Combo in Hairy Cell Leukemia

Video

Enrico Tiacci, MD, discusses updated data of a phase II trial investigating the combination of vemurafenib and rituximab for patients with relapsed/refractory hairy cell leukemia.

Enrico Tiacci, MD, associate professor of hematology, University and Hospital of Perugia, Italy, discusses updated data of a phase II trial (EudraCT 2014-003046-27) investigating the combination of vemurafenib (Zelboraf) and rituximab (Rituxan) for patients with relapsed/refractory hairy cell leukemia.

The trial enrolled 31 patients previously treated with purine analogs to receive 8 weeks of 960 mg of vemurafenib twice daily followed by concomitant 375 mg/m2 of intravenous rituximab every 2 weeks. Consolidation rituximab was given 4 times every 2 weeks after stopping vemurafenib.

Notably, of the 27 evaluable patients, 26 achieved a complete remission (CR). Additionally, 65% of patients had minimal residual disease (MRD) negativity after treatment.

Progression-free survival (PFS) was 100% after a median of 30.5 months for the patients who obtained a MRD-negative CR. Patients who were MRD-positive following treatment had a median PFS of 24.5 months.

Further follow-up will be conducted in this patient cohort, but these results appear promising, concludes Tiacci.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD